All In Biotech

Drug Trial Radar · NCT04644068

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

702

Actual

Start

Nov 12, 2020

Primary completion

May 28, 2027

Study completion May 28, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

  • Ovarian Cancer
  • Breast Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Additional Indications Below for Module 4 and 5
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Gastric Cancer
  • Biliary Cancer
  • Cervical Cancer
  • Endometrial Cancer
  • Small Cell Lung Cancer Only in Module 5

Interventions

  • AZD5305Drug

    Oral PARP inhibitor

  • PaclitaxelDrug

    IV Anti-microtubule agent

  • CarboplatinDrug

    IV Platinum chemotherapeutic

  • T- DxdDrug

    IV Antibody-drug conjugate

  • Dato-DXdDrug

    IV Antibody-drug conjugate

  • CamizestrantDrug

    Oral SERD Molecule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with adverse events/serious adverse eventsTime frame: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
  2. The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study treatment until the end of Cycle 1.

Locations

68 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    New York, New York

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Houston, Texas

  • Research Site

    Heidelberg, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Jining, China

  • Research Site

    Shandong, China

  • Research Site

    Shanghai, China

  • Research Site

    Shanghai, China

  • Research Site

    Taiyuan, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Brno, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Budapest, Hungary

  • Research Site

    Milan, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Modena, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Padova, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Chūōku, Japan

  • Research Site

    Kōtoku, Japan

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Gdansk, Poland

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.